Clinuvel shifts corporate headquarters to US effective Jan. 1, 2027

• Clinuvel announced plans to relocate its corporate headquarters to the U.S., effective Jan. 1, 2027, alongside a strategic reorganization.
• Global workforce to shrink about 10%-20%, with selected functions moved to the U.S. to align costs with revenue and near-term priorities.
• Operating resources to pivot exclusively to the U.S. pipeline and commercial strategy, positioning for deeper U.S. capital access.
• Management cited U.S. investor preference for U.S.-focused listings, stronger sector valuations, and a U.S.-centered late-stage vitiligo program.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clinuvel Pharmaceuticals Limited published the original content used to generate this news brief on July 23, 2026, and is solely responsible for the information contained therein.